title: Avastin, ODAC, and the FDA: are we drafting the right players?
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
mesh_terms: D026683:Advisory Committees; D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D017277:Drug Approval; D005260:Female; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab